Increased Brain Lactate during Depressive Episodes and Reversal Effects by Lithium Monotherapy in Drug-Naive Bipolar Disorder: A 3-T 1H-MRS Study

Journal of Clinical Psychopharmacology

Volumn 37, Issue 1, 2017, Pages 40-45

  Machado Vieira, Rodrigo ^a,b   Zanetti, Marcus V ^a   Otaduy, Maria C ^a   De Sousa, Rafael T ^a   Soeiro De Souza, Marcio G ^a   Costa, Alana C ^a   Carvalho, Andre F ^c   Leite, Claudia C ^a   Busatto, Geraldo F ^a   Zarate, Carlos A ^b   Gattaz, Wagner F ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

Author keywords

bipolar disorder; depression; imaging; lactate; lithium; treatment

Indexed keywords

LACTIC ACID; LITHIUM CARBONATE; PROTON; ANTIDEPRESSANT AGENT; LACTIC ACID DERIVATIVE; LITHIUM DERIVATIVE;

ADULT; ARTICLE; BIPOLAR DEPRESSION; BLOOD SAMPLING; BRAIN; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ENERGY METABOLISM; FAMILY HISTORY; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; LACTATE BLOOD LEVEL; LITHIUM BLOOD LEVEL; MAGNET; MAJOR DEPRESSION; MALE; MENTAL PATIENT; MONOTHERAPY; MOOD DISORDER; NUCLEAR MAGNETIC RESONANCE SCANNER; OPEN STUDY; OUTCOME ASSESSMENT; OUTPATIENT; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; PSYCHOPHARMACOTHERAPY; RISK REDUCTION; TREATMENT DURATION; TREATMENT RESPONSE; BIPOLAR DISORDER; BLOOD; CLINICAL TRIAL; DEPRESSIVE DISORDER, MAJOR; DRUG EFFECTS; METABOLISM; YOUNG ADULT;

ADULT; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; FEMALE; GYRUS CINGULI; HUMANS; LACTATES; LITHIUM COMPOUNDS; MALE; PROTON MAGNETIC RESONANCE SPECTROSCOPY; YOUNG ADULT;

EID: 85000866042     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000616     Document Type: Article

References (32)

1. Quiroz JA, Gray NA, Kato T, et al. Mitochondrially mediated plasticity in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology. 2008;33:2551-2565.
2. de Sousa RT, Zarate CA Jr, Zanetti MV, et al. Oxidative stress in early stage bipolar disorder and the association with response to lithium. J Psychiatr Res. 2014;50:36-41.
3. Hamakawa H, Murashita J, Yamada N, et al. Reduced intracellular pH in the basal ganglia and whole brain measured by 31P-MRS in bipolar disorder. Psychiatry Clin Neurosci. 2004;58:82-88.
4. Lin DD, Crawford TO, Barker PB. Proton MR spectroscopy in the diagnostic evaluation of suspected mitochondrial disease. AJNR Am J Neuroradiol. 2003;24:33-41.
5. Dager SR, Friedman SD, Parow A, et al. Brain metabolic alterations in medication-free patients with bipolar disorder. Arch Gen Psychiatry. 2004;61:450-458.
6. Machado-Vieira R, Andreazza AC, Viale CI, et al. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci Lett. 2007;421:33-36.
7. Andreazza AC, Kauer-Sant'anna M, Frey BN, et al. Oxidative stress markers in bipolar disorder: a meta-analysis. J Affect Disord. 2008;111: 135-144.
8. Konradi C, Eaton M, MacDonald ML, et al. Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch Gen Psychiatry. 2004; 61:300-308.
9. Sun X, Wang JF, Tseng M, et al. Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder. J Psychiatry Neurosci. 2006;31:189-196.
10. de Sousa RT, Machado-Vieira R, Zarate CA Jr, et al. Targeting mitochondrially mediated plasticity to develop improved therapeutics for bipolar disorder. Expert Opin Ther Targets. 2014;18:1131-1147.
11. de Sousa RT, Streck EL, Zanetti MV, et al. Lithium increases leukocyte mitochondrial complex I activity in bipolar disorder during depressive episodes. Psychopharmacology (Berl). 2015;232:245-250.
12. Kim DJ, Lyoo IK, Yoon SJ, et al. Clinical response of quetiapine in rapid cycling manic bipolar patients and lactate level changes in proton magnetic resonance spectroscopy. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1182-1188.
13. Brady RO Jr, Cooper A, Jensen JE, et al. A longitudinal pilot proton MRS investigation of the manic and euthymic states of bipolar disorder. Transl Psychiatry. 2012;2:e160.
14. Drevets WC, Savitz J, Trimble M. The subgenual anterior cingulate cortex in mood disorders. CNS Spectr. 2008;13:663-681.
15. Chu WJ, Delbello MP, Jarvis KB, et al. Magnetic resonance spectroscopy imaging of lactate in patients with bipolar disorder. Psychiatry Res. 2013; 213:230-234.
16. Licht RW. Lithium: still a major option in the management of bipolar disorder. CNS Neurosci Ther. 2012;18:219-226.
17. Haeberle A, Greil W, Russmann S, et al. Mono-and combination drug therapies in hospitalized patients with bipolar depression. Data from the European drug surveillance program AMSP. BMC Psychiatry. 2012; 12:153.
18. Quiroz JA, Machado-Vieira R, Zarate CA Jr, et al. Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects. Neuropsychobiology. 2010;62:50-60.
19. Khairova R, Pawar R, Salvadore G, et al. Effects of lithium on oxidative stress parameters in healthy subjects. Mol Med Rep. 2012;5: 680-682.
20. Machado-Vieira R, Soeiro-de-Souza MG, Richards EM, et al. Multiple levels of impaired neural plasticity and cellular resilience in bipolar disorder: developing treatments using an integrated translational approach. World J Biol Psychiatry. 2014;15:84-95.
21. Friedman SD, Dager SR, Parow A, et al. Lithium and valproic acid treatment effects on brain chemistry in bipolar disorder. Biol Psychiatry. 2004;56:340-348.
22. HAMILTON M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
23. Machado-Vieira R, Zanetti MV, DE Sousa RT, et al. Lithium efficacy in bipolar depression with flexible dosing: a six-week, open-label, proof-of-concept study. Exp Ther Med. 2014;8:1205-1208.
24. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-I/P). New York, NY: Biometrics Research, New York State Psychiatry Institute; 1995.
25. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429-435.
26. Guy W. Early Clinical Drug Evaluation Unit (ECDEU) Assessment Manual for Psychopharmacology-Revised. National Institute of Mental Health: Rockville, MD; 1976:218-222.
27. Corrigan NM, Richards TL, Friedman SD, et al. Improving 1HMRSI measurement of cerebral lactate for clinical applications. Psychiatry Res. 2010;182:40-47.
28. Kreis R. Issues of spectral quality in clinical 1H-magnetic resonance spectroscopy and a gallery of artifacts. NMR Biomed. 2004;17:361-381.
29. Machado-Vieira R, GattazWF, Zanetti MV, et al. A Longitudinal (6-week) 3 T (1)H-MRS study on the effects of lithium treatment on anterior cingulate cortex metabolites in bipolar depression. Eur Neuropsychopharmacol. 2015;25:2311-2317.
30. Xu J, Dydak U, Harezlak J, et al. Neurochemical abnormalities in unmedicated bipolar depression and mania: a 2D 1H MRS investigation. Psychiatry Res. 2013;213:235-241.
31. Diniz BS, Machado-Vieira R, Forlenza OV. Lithium and neuroprotection: translational evidence and implications for the treatment of neuropsychiatric disorders. Neuropsychiatr Dis Treat. 2013;9:493-500.
32. Hashimoto T, Brooks GA.Mitochondrial lactate oxidation complex and an adaptive role for lactate production. Med Sci Sports Exerc. 2008;40: 486-494.